DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
6.46
-0.36 (-5.28%)
At close: Apr 1, 2025, 4:00 PM
6.30
-0.16 (-2.49%)
After-hours: Apr 1, 2025, 4:55 PM EDT
DBV Technologies Employees
As of December 31, 2023, DBV Technologies had 105 total employees, including 104 full-time and 1 part-time employees. The number of employees increased by 19 or 22.09% compared to the previous year.
Employees
105
Change (1Y)
19
Growth (1Y)
22.09%
Revenue / Employee
$40,000
Profits / Employee
-$1,084,762
Market Cap
124.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DBVT News
- 4 days ago - DBV Technologies ADRs Rise After Up to $306.9M in New Financing - Market Watch
- 4 days ago - DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - GlobeNewsWire
- 8 days ago - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - GlobeNewsWire
- 2 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 3 months ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 3 months ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire
- 5 months ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire